Opioid receptors and legal highs:<i>Salvia divinorum</

Clinical Toxicology 46, 146-152

DOI: 10.1080/15563650701241795

Citation Report

#	Article	IF	CITATIONS
1	Legally High? Legal Considerations of <i> Salvia divinorum </i> . Journal of Psychoactive Drugs, 2008, 40, 183-191.	1.7	47
2	Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neurolmage, 2008, 41, 1044-1050.	4.2	79
3	Acquired auditory-visual synesthesia: A window to early cross-modal sensory interactions. Psychology Research and Behavior Management, 2009, 2, 31.	2.8	42
4	Phytochemical Characterization of the Leaves of <i>Mitragyna Speciosa</i> Grown in USA. Natural Product Communications, 2009, 4, 1934578X0900400.	0.5	20
5	<i>In vitro</i> studies on metabolism of salvinorin A. Pharmaceutical Biology, 2009, 47, 1078-1084.	2.9	11
6	Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatographyâ€linear ion trap mass spectrometry. Journal of Mass Spectrometry, 2009, 44, 1249-1261.	1.6	95
7	Quantitative analysis of mitragynine in human urine by high performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 2499-2505.	2.3	49
8	Metabolic Changes in the Rodent Brain after Acute Administration of Salvinorin A. Molecular Imaging and Biology, 2009, 11, 137-143.	2.6	25
9	Determination of mitragynine in rat plasma by LC–MS/MS: Application to pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 2593-2597.	2.3	52
10	Psychoactive drug or mystical incense? Overview of the online available information on Spice products. International Journal of Culture and Mental Health, 2009, 2, 137-144.	0.6	62
11	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 471-477.	4.3	50
12	Salvinorins J from <i>Salvia divinorum</i> : Mutarotation in the Neoclerodane System. Journal of Natural Products, 2009, 72, 1361-1363.	3.0	21
13	Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse. Therapeutic Drug Monitoring, 2010, 32, 544-549.	2.0	66
14	Use of liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine. Analytical and Bioanalytical Chemistry, 2010, 396, 2379-2391.	3.7	44
15	Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC–UV analysis, and its application to a pharmacokinetic study in rat. Analytical and Bioanalytical Chemistry, 2010, 397, 2023-2030.	3.7	53
16	The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. International Journal of Drug Policy, 2010, 21, 283-288.	3.3	191
17	Phase I and II metabolites of speciogynine, a diastereomer of the main ⟨i⟩Kratom⟨/i⟩ alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to lowâ€and highâ€resolution linear ion trap mass spectrometry. Journal of Mass Spectrometry, 2010, 45, 1344-1357.	1.6	41
18	Computational study on the conformations of mitragynine and mitragynaline. Computational and Theoretical Chemistry, 2010, 945, 57-63.	1.5	7

#	Article	IF	Citations
19	Salvia divinorum Epling & J \tilde{A}_i tiva (Maria Pastora) e Salvinorina A: crescente uso recreacional e potencial de abuso. Revista Brasileira De Plantas Medicinais, 2010, 12, 358-362.	0.3	1
20	A Case Report of Inpatient Detoxification after Kratom <i>(Mitragyna speciosa)</i> Dependence. European Addiction Research, 2010, 16, 229-231.	2.4	83
21	New therapeutic potential for psychoactive natural products. Natural Product Reports, 2010, 27, 23-31.	10.3	12
22	Prolonged hallucinations and dissociative self mutilation following use of Salvia divinorumin a bipolar adolescent girl. Journal of Substance Use, 2010, 15, 113-117.	0.7	5
23	Neuropharmacology of the Naturally Occurring \hat{I}^2 -Opioid Hallucinogen Salvinorin A. Pharmacological Reviews, 2011, 63, 316-347.	16.0	106
24	Herbal Medicines for the Management of Opioid Addiction. CNS Drugs, 2011, 25, 999-1007.	5.9	64
25	Zebrafish models to study drug abuse-related phenotypes. Reviews in the Neurosciences, 2011, 22, 95-105.	2.9	127
26	Mitragynine Attenuates Withdrawal Syndrome in Morphine-Withdrawn Zebrafish. PLoS ONE, 2011, 6, e28340.	2.5	69
27	Evaluation of the Effects of Mitragyna speciosa Alkaloid Extract on Cytochrome P450 Enzymes Using a High Throughput Assay. Molecules, 2011, 16, 7344-7356.	3.8	72
28	Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Substance Abuse and Rehabilitation, 2011, 2011, 53.	4.8	37
29	Comprehensive review on herbal medicine for energy intake suppression. Obesity Reviews, 2011, 12, 499-514.	6.5	31
30	Simple, Sensitive, High-Throughput Method for the Quantification of Mitragynine in Rat Plasma Using UPLC-MS and Its Application to an Intravenous Pharmacokinetic Study. Chromatographia, 2011, 74, 703-710.	1.3	28
31	"Legal highs―on the net—Evaluation of UK-based Websites, products and product information. Forensic Science International, 2011, 206, 92-97.	2.2	166
32	Intrahepatic Cholestasis Following Abuse of Powdered Kratom (Mitragyna speciosa). Journal of Medical Toxicology, 2011, 7, 227-231.	1.5	116
33	A Report of Nausea and Vomiting with Discontinuation of Chronic Use of Salvia divinorum. Case Reports in Medicine, 2012, 2012, 1-4.	0.7	8
34	Neurophysiological investigation of idiopathic acquired auditory–visual synesthesia. Neurocase, 2012, 18, 323-329.	0.6	7
36	Hypotheses relating to the function of the claustrum. Frontiers in Integrative Neuroscience, 2012, 6, 53.	2.1	116
37	"Blue is music to my ears― Multimodal synesthesias after a thalamic stroke. Neurocase, 2012, 18, 318-322.	0.6	19

3

#	ARTICLE	IF	CITATIONS
40	Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. Journal of Medical Toxicology, 2012, 8, 15-32.	1.5	299
41	Perspectives on Zebrafish Models of Hallucinogenic Drugs and Related Psychotropic Compounds. ACS Chemical Neuroscience, 2013, 4, 1137-1150.	3.5	54
42	From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience and Biobehavioral Reviews, 2013, 37, 138-151.	6.1	275
43	Availability and Supply of Novel Psychoactive Substances. , 2013, , 55-77.		55
44	Natural Product (Fungal and Herbal) Novel Psychoactive Substances., 2013,, 345-362.		8
45	Tryptamines. , 2013, , 363-381.		11
46	The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK–N–SH neuroblastoma cell. Journal of Ethnopharmacology, 2013, 148, 135-143.	4.1	40
47	An Evidence-Based Systematic Review of Kratom (<i>Mitragyna speciosa</i>) by the Natural Standard Research Collaboration. Journal of Dietary Supplements, 2013, 10, 152-170.	2.6	30
48	A Drug Fatality Involving Kratom. Journal of Forensic Sciences, 2013, 58, S278-9.	1.6	103
49	Epidemiology of adolescent Salvia divinorum use in Canada. Drug and Alcohol Dependence, 2013, 128, 166-170.	3.2	17
50	A simple HPLC–DAD method for the detection and quantification of psychotropic mitragynine in Mitragyna speciosa (ketum) and its products for the application in forensic investigation. Forensic Science International, 2013, 226, 183-187.	2.2	39
51	Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a "Legal High―from the Internet. Journal of Psychoactive Drugs, 2013, 45, 276-286.	1.7	70
52	Kratom Exposures Reported to Texas Poison Centers. Journal of Addictive Diseases, 2013, 32, 396-400.	1.3	44
53	<i>Mitragyna speciosa</i> Korth leaves extracts induced the CYP450 catalyzed aminopyrine-N-demethylase (APND) and UDP-glucuronosyl transferase (UGT) activities in male Sprague-Dawley rat livers. Drug Metabolism and Drug Interactions, 2013, 28, 95-105.	0.3	19
54	Development and validation of a UPLCâ€MS/MS method for the determination of 7â€hydroxymitragynine, a ⟨i⟩μ⟨/i⟩â€opioid agonist, in rat plasma and its application to a pharmacokinetic study. Biomedical Chromatography, 2013, 27, 1726-1732.	1.7	12
55	Central processing of music and its disturbances. Handbook of Clinical Neurophysiology, 2013, , 435-448.	0.0	0
56	Kratom Abuse in Ramathibodi Poison Center, Thailand: A Five-Year Experience. Journal of Psychoactive Drugs, 2013, 45, 404-408.	1.7	42
57	Hazards Associated with the Use of Herbal and Other Natural Products. , 2013, , 335-356.		8

#	Article	IF	Citations
58	Phenibut dependence. BMJ Case Reports, 2013, 2013, bcr2012008381-bcr2012008381.	0.5	25
59	Legal substances and their abuse: Legal highs. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2013, 5, 40-51.	0.1	3
60	Hypotheses Relating to the Function of the Claustrum. , 2014, , 299-352.		13
61	Bath Salts and Other Emerging Toxins. Pediatric Emergency Care, 2014, 30, 47-52.	0.9	6
63	Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 2014, 139, 132-137.	3.2	194
64	Quantitative determination of salvinorin A, a natural hallucinogen with abuse liability, in Internet-available Salvia divinorum and endemic species of Salvia in Taiwan. Journal of Food and Drug Analysis, 2014, 22, 370-378.	1.9	12
66	A critical analysis of national policy relating to legal highs. Nursing Standard (Royal College of) Tj ETQq0 0 0 rgBT	· /Overlock	₹ 10 Tf 50 502
67	The claustrum's proposed role in consciousness is supported by the effect and target localization of Salvia divinorum. Frontiers in Integrative Neuroscience, 2014, 8, 20.	2.1	40
68	Investigating correlates of synthetic marijuana and Salvia use in light and intermittent smokers and college students in a predominantly Hispanic sample Experimental and Clinical Psychopharmacology, 2014, 22, 524-529.	1.8	7
69	The Kratom Experience from Firsthand Reports. , 2014, , 230-261.		O
70	Opioid-Induced Adverse Effects and Toxicity., 2014,, 274-297.		1
71	Screening and Identification of Mitragynine and 7-Hydroxymitragynine in Human Urine by LC-MS/MS. Chromatography (Basel), 2015, 2, 253-264.	1.2	9
72	Pharmacokinetics of mitragynine in man. Drug Design, Development and Therapy, 2015, 9, 2421.	4.3	62
73	Social Functioning of Kratom <i>(Mitragyna speciosa)</i> li>Users in Malaysia. Journal of Psychoactive Drugs, 2015, 47, 125-131.	1.7	76
74	Auditory synesthesias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 129, 389-407.	1.8	0
7 5	Salvinorin A content in legal high products of Salvia divinorum sold in Mexico. Forensic Science International, 2015, 249, 197-201.	2.2	11
76	Attention: the claustrum. Trends in Neurosciences, 2015, 38, 486-495.	8.6	175
77	Kratom (Mitragyna speciosa) Use, Addiction Potential, and Legal Status. , 2016, , 903-911.		4

#	ARTICLE	IF	CITATIONS
78	Depressant Effects of Salvia divinorum Involve Disruption of Physiological Sleep. Phytotherapy Research, 2016, 30, 1137-1145.	5.8	9
79	Neurobiology of Kratom and its main alkaloid mitragynine. Brain Research Bulletin, 2016, 126, 29-40.	3.0	75
80	Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Research Bulletin, 2016, 126, 41-46.	3.0	151
81	Do You Get What You Paid For? An Examination of Products Advertised as Kratom. Journal of Psychoactive Drugs, 2016, 48, 330-335.	1.7	27
82	Abuse potential and adverse cognitive effects of mitragynine (kratom). Addiction Biology, 2016, 21, 98-110.	2.6	104
83	Plan for quality improvement: the  Legal High' Guide. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2016, 8, 36-40.	0.1	1
84	Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. Journal of Medical Toxicology, 2016, 12, 341-349.	1.5	93
85	The prevalence of low back pain and its associated factors in Thai rubber farmers. Journal of Occupational Health, 2016, 58, 534-542.	2.1	21
86	Chemical characterization and in vitro cyto- and genotoxicity of †legal high†products containing Kratom (Mitragyna speciosa). Forensic Toxicology, 2016, 34, 213-226.	2.4	9
87	The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. International Journal of Legal Medicine, 2016, 130, 127-138.	2.2	150
88	New psychoactive substances of natural origin: AÂbrief review. Journal of Food and Drug Analysis, 2017, 25, 461-471.	1.9	60
89	The effects of kratom on restraint–stress-induced analgesia and its mechanisms of action. Journal of Ethnopharmacology, 2017, 205, 178-185.	4.1	5
90	Pharmacology and Structure-Activity Relationship of Natural Products With Psychoactive Effects From Salvia divinorum, Mitragyna speciosa, and Ayahuasca. Studies in Natural Products Chemistry, 2017,, 1-44.	1.8	1
91	Evaluation of pharmacokinetics and blood-brain barrier permeability of mitragynine using in vivo microdialysis technique. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 43-47.	2.8	22
92	Determination of Mitragynine in <i>Mitragyna speciosa</i> Raw Materials and Finished Products by Liquid Chromatography with UV Detection: Single-Laboratory Validation. Journal of AOAC INTERNATIONAL, 2017, 100, 18-24.	1.5	17
93	Cardiovascular Toxicities of Herbal Products: An Overview of Selected Compounds., 2017,, 363-383.		0
94	A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom. Journal of Ethnopharmacology, 2017, 202, 302-325.	4.1	74
95	Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug and Alcohol Dependence, 2017, 180, 340-348.	3.2	96

#	ARTICLE	IF	Citations
96	Screening of Hallucinogenic Compounds and Genomic Characterisation of 40 Anatolian <i>Salvia</i> Species. Phytochemical Analysis, 2017, 28, 541-549.	2.4	4
97	Introducing… Kratom. Journal of Emergency Nursing, 2017, 43, 373-374.	1.0	11
98	Current Opiate and Opioid Hazards in Children and Adolescents. Clinical Pediatric Emergency Medicine, 2017, 18, 173-180.	0.4	3
99	Abnormal sensory experiences, synaesthesia, and neurodevelopmental disorders. Journal of Autism and Developmental Disorders, 2017, 47, 2942-2944.	2.7	0
100	A High By Any Other Name: Exploring the Motivations for Consumption of "Legal Highs― Deviant Behavior, 2017, 38, 549-560.	1.7	5
101	Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom. Frontiers in Psychiatry, 2017, 8, 62.	2.6	49
102	When good times go bad: managing & amp; Isquo; legal high & amp; rsquo; complications in the emergency department. Open Access Emergency Medicine, 2018, Volume 10, 9-23.	1.3	13
103	Development of an immunochromatographic strip incorporating antiâ€mitragynine monoclonal antibody conjugated to colloidal gold for kratom alkaloids detection. Drug Testing and Analysis, 2018, 10, 1168-1175.	2.6	15
104	Plant Medicines, Healing and Psychedelic Science. , 2018, , .		7
105	Designer drugs: Review and implications for emergency management. Human and Experimental Toxicology, 2018, 37, 94-101.	2.2	17
106	How do social work novices and experts solve professional problems? A micro-analysis of epistemic activities and the use of evidence. European Journal of Social Work, 2018, 21, 3-19.	0.9	17
107	Clinical outcomes after Kratom exposures: A poison center case series. American Journal of Emergency Medicine, 2018, 36, 166-168.	1.6	31
108	The Scheduling of Kratom and Selective Use of Data. Journal of Psychoactive Drugs, 2018, 50, 114-120.	1.7	32
109	Death from Kratom toxicity and the possible role of intralipid. Journal of the Intensive Care Society, 2018, 19, 61-63.	2.2	39
110	Alkaloid Profiles and Activity in Different <i>Mitragyna speciosa</i> Strains. Natural Product Communications, 2018, 13, 1934578X1801300.	0.5	6
111	Inhibition of UGT2B7 Enzyme Activity in Human and Rat Liver Microsomes by Herbal Constituents. Molecules, 2018, 23, 2696.	3.8	19
112	Opioids in the Frame of New Psychoactive Substances Network: A Complex Pharmacological and Toxicological Issue. Current Molecular Pharmacology, 2018, 11, 97-108.	1.5	40
113	Kratom: a dangerous player in the opioid crisis. Journal of Community Hospital Internal Medicine Perspectives, 2018, 8, 107-110.	0.8	30

#	Article	IF	CITATIONS
114	Examining the Therapeutic Potential of Kratom Within the American Drug Regulatory System. , 2018, , 71-85.		1
115	Psychodysleptica., 2018,, 1-392.		0
116	Fatal Mitragynine-Associated Toxicity in Canada. Academic Forensic Pathology, 2018, 8, 340-346.	0.3	19
117	An unusual cause for neonatal abstinence syndrome. Paediatrics and Child Health, 2019, 24, 12-14.	0.6	23
118	Characteristics of deaths associated with kratom use. Journal of Psychopharmacology, 2019, 33, 1102-1123.	4.0	67
119	Discovering Alternative Treatments for Opioid Use Recovery Using Social Media. , 2019, , .		62
120	Kratom policy: The challenge of balancing therapeutic potential with public safety. International Journal of Drug Policy, 2019, 70, 70-77.	3.3	83
121	A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products. Forensic Science International, 2019, 299, 195-202.	2.2	25
122	The Pharmacology of Visual Hallucinations in Synucleinopathies. Frontiers in Pharmacology, 2019, 10, 1379.	3.5	36
123	Kratom Withdrawal: A Systematic Review with Case Series. Journal of Psychoactive Drugs, 2019, 51, 12-18.	1.7	51
124	Long-Term Cognitive Effects of Kratom (<i>Mitragyna speciosa</i> Korth.) Use. Journal of Psychoactive Drugs, 2019, 51, 19-27.	1.7	35
125	A Mild Panic? Media Accounts of Kratom. Deviant Behavior, 2020, 41, 1258-1267.	1.7	4
126	On the G Protein-Coupled Receptor Neuromodulation of the Claustrum. Neurochemical Research, 2020, 45, 5-15.	3.3	7
127	S-adenosyl-l-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations. Brain, Behavior, and Immunity, 2020, 85, 152-161.	4.1	4
128	DARK Classics in Chemical Neuroscience: Kratom. ACS Chemical Neuroscience, 2020, 11, 3870-3880.	3.5	16
129	Kratom (Mitragyna speciosa): worldwide issues. Current Opinion in Psychiatry, 2020, 33, 312-318.	6.3	19
130	The internet market for Kratom, an opioid alternative and variably legal recreational drug. International Journal of Drug Policy, 2020, 78, 102715.	3.3	25
131	A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management. Journal of Psychoactive Drugs, 2020, 52, 447-452.	1.7	23

#	Article	IF	CITATIONS
132	Management of overdoses of salvia, kratom, and psilocybin mushrooms: a literature review. Expert Review of Clinical Pharmacology, 2020, 13, 847-856.	3.1	5
133	Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. Pain and Therapy, 2020, 9, 55-69.	3.2	90
134	Counterfeit formulations: analytical perspective on anorectics. Forensic Toxicology, 2021, 39, 1-25.	2.4	5
135	Kratom (Mitragyna speciosa Korth.): A description on the ethnobotany, alkaloid chemistry, and neuropharmacology. Studies in Natural Products Chemistry, 2021, 69, 195-225.	1.8	6
136	Psychoactive plants and phytochemicals. , 2021, , 121-150.		0
137	Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects. Pharmaceuticals, 2021, 14, 116.	3.8	13
138	Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. Frontiers in Psychiatry, 2021, 12, 640218.	2.6	13
139	Kratom: The safe legal high?. Epilepsy and Behavior, 2021, 117, 107882.	1.7	5
140	Intracerebral hemorrhage after kratom ingestion. JAAPA: Official Journal of the American Academy of Physician Assistants, 2021, 34, 33-36.	0.3	4
141	Kratom: A systematic review of toxicological issues. Wiley Interdisciplinary Reviews Forensic Science, 2022, 4, .	2.1	7
142	Pressure Necrosis Requiring Fasciotomy After Kratom Overdose. Journal of Addiction Medicine, 2022, 16, 252-253.	2.6	9
143	Kratom-induced transaminitis with subsequent precipitated opioid withdrawal following naltrexone. Mental Health Clinician, 2021, 11, 220-224.	1.0	7
144	Kratom exposures among older adults reported to U.S. poison centers, 2014–2019. Journal of the American Geriatrics Society, 2021, 69, 2176-2184.	2.6	12
145	Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample. American Journal of Preventive Medicine, 2021, 61, 240-245.	3.0	41
146	Availability and supply of novel psychoactive substances. , 2022, , 57-84.		1
147	Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 2020, 208, 107849.	3.2	98
148	Cerebellum and endocannabinoid receptors: a new neurobiological link for mitragynine (Mitragyna) Tj ETQq0 0 0	rgBT Ove	erlock 10 Tf 5
149	Physicochemical Characterization of Mitragyna speciosa Alkaloid Extract and Mitragynine using In Vitro High Throughput Assays. Combinatorial Chemistry and High Throughput Screening, 2018, 20, 796-803.	1.1	17

#	Article	IF	CITATIONS
150	Cytotoxic Effects of Salvinorin A, A Major Constituent of Salvia divinorum. Medicinal Chemistry, 2016, 12, 432-440.	1.5	4
151	"Legal Highs―– New Players in the Old Drama. Current Drug Abuse Reviews, 2011, 4, 122-130.	3.4	54
152	A Mass Spectrometric Study of Kratom Compounds by Direct Infusion Electrospray Ionization Triple Quadrupole Mass Spectrometry. Detection, 2016, 04, 66-72.	0.8	4
153	Opiates and Opioids. , 2008, , 367-374.		0
154	Hallucinogens. , 2010, , 2010-2018.		0
155	Chemical analysis of substitute drugs of abuse – "legal highs―from Lubuskie province, Poland. Journal of Medical Science, 2014, 83, 101-107.	0.7	0
156	Panorama actual en el uso de drogas emergentes. Health and Addictions / Salud Y Drogas, 2014, 14, 47-58.	0.2	0
157	Designer Drugs: A Review of Literature. Arab Journal of Forensic Sciences and Forensic Medicine, 2015,	0.1	0
158	Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study. Yale Journal of Biology and Medicine, 2020, 93, 229-238.	0.2	18
159	Clinical Pharmacology of the Dietary Supplement Kratom (<i>Mitragyna speciosa</i>). Journal of Clinical Pharmacology, 2022, 62, 577-593.	2.0	9
160	Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy. Neuroscience Letters, 2022, 773, 136500.	2.1	7
161	The chemical induction of synaesthesia. Human Psychopharmacology, 2022, 37, e2832.	1.5	2
162	Mitragyna Species as Pharmacological Agents: From Abuse to Promising Pharmaceutical Products. Life, 2022, 12, 193.	2.4	8
163	Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A. Natural Product Communications, 2009, 4, 907-10.	0.5	36
165	Current Understanding of the Effects and Potential Clinical Utility of Kratom: A Review. Journal of Psychiatric Practice, 2022, 28, 92-97.	0.7	1
166	Sulfobutylation of Beta-Cyclodextrin Enhances the Complex Formation with Mitragynine: An NMR and Chiroptical Study. International Journal of Molecular Sciences, 2022, 23, 3844.	4.1	5
167	Effect of Feed Supplement Containing Dried Kratom Leaves on Apparent Digestibility, Rumen Fermentation, Serum Antioxidants, Hematology, and Nitrogen Balance in Goats. Fermentation, 2022, 8, 131.	3.0	9
168	On the relevance of toxicological and hygienic assessment and market regulation of herbal dietary supplements made from Mitragyna speciosa Korth (Rubiaceae family). One Health and Nutrition Problems of Ukraine, 2021, 55, 30-43.	0.2	0

#	Article	IF	CITATIONS
169	Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample. Frontiers in Pharmacology, 2021, 12, 789075.	3.5	12
170	The Prevalence and Psychosocial Correlates of Ketum (Mitragyna speciosa) Use among Individuals on Methadone Maintenance Therapy Programme in Hospital Taiping, Malaysia. Healthcare (Switzerland), 2022, 10, 746.	2.0	2
173	Kratom-Associated Mixed Cholestatic-Hepatocellular Liver Injury in a Patient With Long COVID: A case Report. Clinical Medicine Insights: Case Reports, 2022, 15, 117954762211328.	0.7	1
174	Drug testing for mitragynine and kratom: Analytical challenges and medicoâ€legal considerations. Drug Testing and Analysis, 2023, 15, 213-219.	2.6	2
175	Variations in mitragynine content in the naturally growing Kratom (Mitragyna speciosa) population of Thailand. Frontiers in Plant Science, $0,13,.$	3.6	4
176	Plant Food and Incense: The New Substances of Abuse. Annals of the Academy of Medicine, Singapore, 2013, 42, 356-357.	0.4	O
177	Controversial usages of kratom (<i>Mitragyna speciosa</i>): For good or for evil. World Journal of Pharmacology, 0, 11, 16-26.	2.3	0
178	Kratom: A Bibliometric Analysis of Scientific Publications. Journal of Psychoactive Drugs, 2024, 56, 14-22.	1.7	O
179	Patterns of polysubstance use among adults in Malaysiaâ€"A latent class analysis. PLoS ONE, 2023, 18, e0264593.	2.5	1
180	Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects. Journal of Ethnopharmacology, 2023, 317, 116779.	4.1	2
181	The Great Imitator: A Case of Accidental Kratom Overdose. Cureus, 2023, , .	0.5	0
182	KRATOM AND ITS EFFECTS ON AN ORGANISM. Military Medical Science Letters (Vojenske Zdravotnicke) Tj ETQq1	1.0.78431	14 rgBT /0\
183	Kratom use and mental health: A systematic literature review and case example. Journal of Addictive Diseases, 0, , 1-12.	1.3	1
184	Molecular basis of opioid receptor signaling. Cell, 2023, 186, 5203-5219.	28.9	3
185	An insight review on the neuropharmacological effects, mechanisms of action, pharmacokinetics and toxicity of mitragynine. Biomedicine and Pharmacotherapy, 2024, 171, 116134.	5.6	0
186	Knowledge of Kratom among Alabama Pharmacists. Pharmacy (Basel, Switzerland), 2024, 12, 6.	1.6	O
187	Effects of kratom on driving: Results from a cross-sectional survey, ecological momentary assessment, and pilot simulated driving Study. Traffic Injury Prevention, 2024, 25, 594-603.	1.4	0